Semaglutide vs Tirzepatide: The Only Head-to-Head Trial in the Class

Semaglutide is a 31-residue acylated GLP-1 analogue.[4] Everything it does runs through the GLP-1 receptor: slowed gastric emptying, central appetite effects, glucose-dependent insulin secretion. That single-receptor design is what makes it the cleanest available tool compound for GLP-1 receptor pharmacology.

Tirzepatide is a 39-residue lipidated peptide agonising both the GIP and the GLP-1 receptor from one molecule, with potency weighted toward GIP.[3] The GIP arm is the part that was not obvious: GIP-receptor pharmacology in metabolic disease had a contested literature, and the compound's trial results are the strongest argument that adding it does something.

Structurally the two are further apart than the shared "GLP-1" label suggests. Semaglutide is built on the native GLP-1 backbone; tirzepatide is built on a GIP-based backbone engineered for dual activity.

Amino Acid Sequence

Amino Acid Sequence

Frías et al., New England Journal of Medicine 2021: a 40-week open-label randomised trial in adults with type 2 diabetes on metformin, comparing tirzepatide at 5, 10 and 15 mg against semaglutide 1 mg. Tirzepatide produced greater reductions in HbA1c and in body weight across its dose arms.[1]

Two caveats belong with that result and are routinely dropped. The trial was open-label, not double-blind. And the semaglutide comparator was 1 mg, the diabetes dose at the time, not the 2.4 mg dose used in the obesity trials. Neither invalidates the finding; both bound how far it generalizes.

• ·Semaglutide, obesity. STEP 1: 68 weeks, randomised, double-blind, placebo-controlled, mean weight change about -14.9% against -2.4% for placebo.[2]
• ·Semaglutide, cardiovascular. SUSTAIN-6 in type 2 diabetes,[5] and SELECT in adults with overweight or obesity and established cardiovascular disease but without diabetes, reporting a lower rate of major adverse cardiovascular events against placebo.[6] SELECT is the deepest outcome dataset either compound has.
• ·Tirzepatide, obesity. SURMOUNT-1: 72 weeks, mean weight reduction roughly 15% to 21% across dose arms against 3% for placebo.[7]
• ·Tirzepatide, other indications. SURMOUNT-4 withdrawal design,[8] and SURMOUNT-OSA in obstructive sleep apnoea.[9]
• ·Cardiovascular outcomes. Semaglutide has the larger published cardiovascular-outcome record. That is a genuine asymmetry and it runs the other way from the weight comparison.

• ·Mass. Semaglutide near 4114 Da, tirzepatide near 4813 Da. Both lipidated; tirzepatide is the longer and harder synthesis.
• ·Characteristic quality failure. For semaglutide, incomplete or absent acylation, which changes mass and half-life while looking similar on a purity trace. For tirzepatide, deletion sequences from a longer chain.
• ·Price. Semaglutide is typically the cheaper per milligram of the two, reflecting synthesis difficulty rather than any pharmacological ranking.
• ·Approved counterparts. Both molecules exist as approved medicines through the pharmacy channel. Research-grade vials of either are outside those authorizations entirely.

Identity by mass spectrometry against the expected mass, HPLC purity, and measured content against the labelled amount. The two masses are far enough apart that an identity report distinguishes them unambiguously, which matters because they are the two most commonly substituted-for compounds in the category.

Certificates for both are published before sale and verifiable on the testing laboratory's own database.

Published Certificate

Batch

SEMA-CA-26F-10

Purity (HPLC)

99.504%

Measured content

11.27 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Published Certificate

Select strength

10mg15mg30mg60mg

Batch

TIRZ-CA-26G-10

Purity (HPLC)

99.634%

Measured content

11.42 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

For isolating GLP-1 receptor pharmacology, semaglutide is the correct tool precisely because it does one thing. For questions about GIP-receptor contribution, or about combined incretin pharmacology, tirzepatide is the only compound that provides both arms in one molecule and the only one with a direct head-to-head trial behind it.

Both are stocked with published certificates and supplied strictly as research materials. The triple-agonist comparison is at retatrutide vs tirzepatide.

Available at Eppix Labs

Buy Semaglutide Canada | GLP-1

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $70.00 CADIn stock

Available at Eppix Labs

Buy Tirzepatide Canada | GIP/GLP-1

10mg · 15mg · 30mg · 60mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $35.00 CADIn stock